Representative before the EPO

Technology company logo thumb
no operation time available
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Employment test 51 - 200 employees
Company dna mathys and squire llp
no operation time available
Headquarter in London and 5 offices
active in Legal Services and Matchmaking and Trading

We have observed 8 EP applications Paul Martin Brial Commander has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after January 19, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP13183819

Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses

IPC classification:
A61K 39/12
Applicant:
Sanofi Pasteur SA
Agent:
Paul Martin Brial Commander, Sanofi Pasteur SA
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13740025

VACCINE COMPOSITIONS FOR PREVENTION AGAINST DENGUE VIRUS INFECTION

IPC classification:
A61K 39/12, A61K 39/295
Applicant:
Sanofi Pasteur SA
Agent:
Paul Martin Brial Commander, Sanofi Pasteur SA
Status:
GRANT OF PATENT INTENDED
EP13741748

VACCINE COMPOSITIONS

IPC classification:
A61K 39/12, A61K 39/295
Applicant:
Sanofi Pasteur SA
Agent:
Paul Martin Brial Commander, Sanofi Pasteur SA
Status:
GRANT OF PATENT INTENDED
EP13774363

VACCINATION AGAINST JAPANESE ENCEPHALITIS, MEASLES, MUMPS AND RUBELLA

IPC classification:
A61K 39/295, A61P 31/14
Applicant:
Sanofi Pasteur SA
Agent:
Paul Martin Brial Commander, Sanofi Pasteur SA
Status:
EXAMINATION IN PROGRESS
EP13163182

AAV virions with decreased immunoreactivity and uses therefor

IPC classification:
C07K 1/00, C07K 14/00, C07K 14/015, C07K 17/00, C12N 15/00, C12N 15/09, C12N 15/63, C12N 15/70, C12N 15/74, C12N 15/864
Agent:
Multiple attorneys, Mathys & Squire LLP
Status:
PATENT GRANTED
EP13163168

AAV virions with decreased immunoreactivity and uses therefor

IPC classification:
C07K 1/00, C07K 14/00, C07K 14/015, C07K 17/00, C12N 15/00, C12N 15/09, C12N 15/63, C12N 15/70, C12N 15/74, C12N 15/864
Applicant:
Genzyme Corporation
Agent:
Multiple attorneys, Mathys & Squire LLP
Status:
PATENT GRANTED
EP15759746

VACCINE COMPOSITIONS AGAINST DENGUE VIRUS DISEASES

IPC classification:
A61K 39/00, A61K 39/12, A61K 39/295
Applicant:
Sanofi Pasteur SA
Agent:
Paul Martin Brial Commander, Sanofi Pasteur SA
Status:
Request for examination was made
EP15817288

MULTIMERIZATION OF RECOMBINANT PROTEIN BY FUSION TO A SEQUENCE FROM LAMPREY

IPC classification:
C07K 19/00, C12N 15/62
Applicant:
Sanofi Pasteur SA
Agent:
Paul Martin Brial Commander, Sanofi Pasteur SA
Status:
Request for examination was made

Please Sign in to use this feature